Resona Asset Management Co. Ltd. lowered its position in Pfizer Inc. (NYSE:PFE – Free Report) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,919,310 shares of the biopharmaceutical company’s stock after selling 100,455 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Pfizer were worth $47,821,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Horizon Financial Services LLC raised its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter worth approximately $29,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.
Pfizer Stock Performance
Shares of Pfizer stock opened at $25.31 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 52 week low of $22.64 and a 52 week high of $28.75. The stock has a market capitalization of $144.22 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The firm has a fifty day moving average of $26.96 and a two-hundred day moving average of $26.20.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on PFE shares. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Finally, Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.84.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
